Market Overview

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Share:

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces participation at the following upcoming conferences:

  • Citi's 14ᵗʰ Annual Biotech Conference
    • Wednesday, September 4, 2019
  • Baird's 2019 Global Healthcare Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, September 5, 2019, at 12:15 p.m. Eastern Time.
  • Morgan Stanley's 17th Annual Global Healthcare Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Wednesday, September 11, 2019, at 11:40 a.m. Eastern Time
  • Oppenheimer's Fall Summit Focused on Specialty Pharma and Rare Disease Companies
    • Monday, September 23, 2019
  • Ladenburg Thalmann's 2019 Healthcare Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, September 24, 2019, at 12:00 p.m. Eastern Time

A live audio webcast of the presentations will be available on the Investors section of the company's website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket") is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket's multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's first two clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, and Leukocyte Adhesion Deficiency-I (LAD-I), a serve pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal. Rocket's first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket's pre-clinical pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO). For more information about Rocket, please visit www.rocketpharma.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com